Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 9/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178345 | 0.86 | PPARG (0.40) | IDO1ESR1BACE1MEN1KMT2A | |
| SCHEMBL12855670 | 0.84 | AGXT (0.52) | IDO1TSHR | |
| SCHEMBL15489965 | 0.84 | TDP1 (0.37) | BACE1KMT2A | |
| SCHEMBL31138172 | 0.83 | BACE1 (0.36) | IDO1ESR1BACE1 | |
| SCHEMBL2876790 | 0.83 | CA2 (0.45) | BACE1TSHR | |
| SCHEMBL2821530 | 0.83 | ESR1 (0.45) | IDO1ESR1BACE1ESR2MEN1 | |
| SCHEMBL3426875 | 0.82 | AGXT (0.32) | IDO1BACE1CYP3A4 | |
| SCHEMBL18954528 | 0.82 | MAOB (0.41) | IDO1ABAT | |
| SCHEMBL7262934 | 0.82 | AGXT (0.32) | IDO1BACE1 | |
| SCHEMBL133816 | 0.82 | MAOB (0.39) | IDO1CYP3A4HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | disclosed |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | SEAPORT THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260041661-A1 | THREE-COMPONENT PRODRUG, PHARMACEUTICAL COMPOSITION THEREOF, AND MEDICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2026-02-12 | — | — | US | disclosed |
| EP-4676535-A1 | MULTI-ALBUMIN BINDING COMPOUNDS | Ascendis Pharma A/S (DK) | 2026-01-14 | — | — | EP | disclosed |
| US-20250352510-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-11-20 | — | — | US | disclosed |
| US-20250213522-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-07-03 | — | — | US | disclosed |
| EP-4578865-A2 | LYMPH DIRECTING PRODRUGS | Monash University (AU) | 2025-07-02 | — | — | EP | disclosed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | disclosed |
| US-20250041306-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-119306780-A | Lipid prodrugs of pregnane neurosteroids and uses thereof | 海港治疗公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-1362053-A4 | TERMINALLY-BRANCHED POLYMERIC LINKERS AND POLYMERIC CONJUGATES CONTAINING THE SAME | ENZON INC (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004012735-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| EP-1362053-A2 | TERMINALLY-BRANCHED POLYMERIC LINKERS AND POLYMERIC CONJUGATES CONTAINING THE SAME | ENZON, INC. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002065988-A2 | TERMINALLY-BRANCHED POLYMERIC LINKERS AND POLYMERIC CONJUGATES CONTAINING THE SAME | ENZON, INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | disclosed |
| US-5231113-A | Skin disorders, immunology or wound healing agents | ALLERGAN, INC. (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0337689-B1 | TETRALIN ESTERS OF PHENOLS OR BENZOIC ACIDS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1993-03-10 | — | — | EP | disclosed |
| US-5130335-A | Treatment of skin disorders | ALLERGAN, INC. (US) | 1992-07-14 | — | — | US | disclosed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | disclosed |
| EP-0337689-A1 | Tetralin esters of phenols or benzoic acids having retinoid like activity | ALLERGAN, INC (US) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041306-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | ADAMTS1, UCHL3, ADAM33 | IDO1 1451/4885ESR1 1044/4885BACE1 100/4885 |
| US-20260041661-A1 | THREE-COMPONENT PRODRUG, PHARMACEUTICAL COMPOSITION THEREOF, AND MEDICAL USE THEREOF | FPGS, TFB2M, UFM1 | IDO1 1752/4885ESR1 4143/4885BACE1 55/4885 |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MALT1, CES1, LIPA | IDO1 1549/4885ESR1 2160/4885BACE1 2310/4885 |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | JAK1, JAK3, JAK2 | IDO1 223/4885ESR1 3181/4885BACE1 4312/4885 |
| US-20250213522-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | IDO1 2252/4885ESR1 1606/4885BACE1 3195/4885 |
| US-20250352510-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | IDO1 2252/4885ESR1 1606/4885BACE1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.